Methamphetamine Use Disorder: Symptoms, Psychosis Risk, and Care

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Methamphetamine use disorder is a clinically recognized pattern of methamphetamine use involving impaired control, recurrent use despite substantial harm, and clinically significant effects on health or functioning. The condition can involve intense craving, sleep disruption, depression, cardiovascular disease, infectious risks, and episodes of paranoia or psychosis. Diagnosis is based on a careful clinical history and established substance use disorder criteria. Treatment centers on evidence-based behavioral care, particularly contingency management, coordinated treatment of psychiatric and medical conditions, and sustained recovery support. Methamphetamine-related psychosis requires separate assessment because it may be transient, recurrent, persistent, or associated with an independent psychotic disorder. The ASAM and AAAP clinical practice guideline provides the central evidence-based framework.

A person experiencing chest pain, severe agitation, very high body temperature, a seizure, loss of consciousness, suicidal intent, or hallucinations accompanied by imminent danger needs emergency medical evaluation. These findings may reflect stimulant toxicity or another acute illness, and medical assessment takes priority over a routine addiction visit. The goal of treatment is to protect life, relieve suffering, restore functioning, and build a sustainable recovery pathway without stigma or coercion. ASAM and AAAP identify these presentations as reasons to escalate the level of care.

What Is Methamphetamine Use Disorder?

Methamphetamine is a potent synthetic central nervous system stimulant in the amphetamine family. Its pharmacologic effects include increased wakefulness and changes in attention, energy, appetite, reward processing, and sympathetic nervous system activity. Methamphetamine may be swallowed, inhaled, smoked, or injected. Route of administration affects the speed of effects and associated health risks, but a route by itself neither establishes nor excludes a disorder. Illicitly manufactured products have uncertain purity and may contain additional substances. The National Institute on Drug Abuse describes the associated neurological, cardiovascular, and behavioral harms.

The diagnosis refers to a repeated pattern with recognizable behavioral and functional consequences. Substance use means exposure to a drug; risky use indicates a pattern with increased probability of harm; misuse describes use outside medical direction or in harmful circumstances; and substance use disorder is a clinical diagnosis. Addiction is a commonly used clinical and scientific construct emphasizing compulsive engagement despite consequences. Physical dependence means neuroadaptation that can produce withdrawal after reduction or discontinuation. Tolerance refers to reduced effects with repeated exposure or a need for more substance to obtain a similar effect. Physiological adaptation alone does not demonstrate the impaired control that defines a disorder. These distinctions matter for explaining symptoms and choosing care.

Clinically, methamphetamine use disorder belongs within the broader category of stimulant use disorders. Its distinct profile warrants methamphetamine-specific assessment because duration of action, patterns of repeated dosing, sleep deprivation, psychosis risk, cardiovascular complications, and concurrent opioid exposure can affect presentation. Treatment research often groups methamphetamine and other amphetamine-type stimulants, while some studies focus specifically on methamphetamine. Results from mixed stimulant samples require attention to the studied population before they are applied to an individual patient. The 2024 ASAM/AAAP guideline addresses both shared stimulant principles and important substance-specific considerations.

Diagnostic Symptoms and Severity

How clinicians apply substance use disorder criteria

Under DSM-5-TR, the relevant stimulant use disorder framework evaluates eleven manifestations within a twelve-month period, including larger amounts or longer use than intended, unsuccessful efforts to reduce use, substantial time spent obtaining or recovering from use, craving, failure to meet major obligations, social or interpersonal problems, abandonment of activities, hazardous use, continued use despite physical or psychological harm, tolerance, and withdrawal. A diagnosis requires at least two qualifying criteria with clinically significant distress or impairment. Two or three criteria indicate mild severity, four or five moderate severity, and six or more severe severity. The clinician evaluates context, timing, and alternative explanations, rather than simply counting symptoms from a checklist. The formal diagnostic assessment also distinguishes expected effects of medically supervised stimulant treatment from misuse or disorder. ASAM and AAAP discuss structured diagnostic assessment and evaluation of associated risks.

Common clinical manifestations include repeated use despite clear intentions to stop, missed work or school, disrupted family responsibilities, spending substantial time obtaining or recovering from methamphetamine, an escalating preoccupation with use, diminished attention to nutrition and sleep, and recurring use despite anxiety, paranoia, dental disease, or cardiac symptoms. Individuals may experience intense cravings when exposed to people, locations, feelings, or routines associated with prior use. Withdrawal-related dysphoria and fatigue can strengthen the urge to use again. The diagnostic significance lies in the pattern and impact over time, rather than in any single symptom.

A clinical interview should also establish the length and pattern of use, methods of administration, previous attempts to change use, periods of abstinence, co-occurring alcohol, opioids, cannabis, benzodiazepines or medications, and the patient's own priorities for care. Questions about housing, work, relationships, violence exposure, sexual health, previous overdose, and access to food or transportation often identify immediate barriers to treatment. A respectful interview improves the likelihood of reliable disclosure. The ASAM/AAAP guideline recommends comprehensive assessment that incorporates psychiatric, medical, substance-related, and social needs.

Screening, toxicology, and formal diagnosis

Screening identifies patients who may benefit from further evaluation. Validated brief tools and structured questions help detect risky stimulant use, but no screening score alone establishes methamphetamine use disorder. Urine or other toxicology tests can provide evidence of recent exposure within a detection window that varies with timing, assay, and individual factors. A positive result does not measure current intoxication, establish impairment, determine frequency of use, or independently diagnose addiction. A negative result does not exclude an established disorder. Clinicians should explain the purpose and limitations of testing and use confirmatory methods when a result is consequential or unexpected. ASAM and AAAP address the clinical role of toxicology within a broader assessment.

Why Methamphetamine Can Become Compulsive

Methamphetamine increases synaptic monoamine signaling, notably dopamine and norepinephrine, and changes neural systems involved in reward, salience, arousal, and behavioral control. Repeated exposure can shift attention toward drug-associated cues and encourage strongly learned habits. Craving may then emerge from an interaction among expected reward, negative mood, stress, memory, environmental cues, and reduced access to alternative sources of reinforcement. Neurobiological explanations describe one part of a multidimensional disorder; the clinical course is shaped by developmental, psychological, social, and economic conditions. See the NIDA methamphetamine research overview.

The cycle often begins with reinforcing effects such as heightened energy, confidence, or relief from fatigue. Repeated use may be followed by sleep loss, emotional instability, and increasingly difficult periods after intoxication. A person can come to use methamphetamine both for anticipated effects and to escape unpleasant states. Sensitization to drug cues and habit learning can persist even as the initial desirable effects diminish. These processes explain why advice or a short period of withdrawal management may fail to address the determinants of recurrence. Recovery requires changes in context, coping, daily routines, and access to rewarding alternatives.

Genetic liability, early adversity, co-occurring mental disorders, social isolation, unstable housing, and exposure to high-availability environments can contribute to vulnerability. Their influence is probabilistic; they do not determine any individual's outcome. Some people begin using to remain awake for demanding work, manage distress, enhance social or sexual experiences, or cope with other difficulties. A scientifically credible assessment asks which functions methamphetamine serves in the person's life and how treatment can replace those functions with safer supports. ASAM and AAAP recommend treating co-occurring conditions and addressing recovery supports concurrently.

Physical, Psychological, and Social Health Effects

Cardiovascular, metabolic, and neurological risks

Acute stimulant exposure can elevate heart rate and blood pressure and contribute to chest pain, arrhythmias, hyperthermia, seizures, stroke, myocardial injury, and severe agitation. Long-term use is associated with cardiomyopathy and other cardiovascular disease, although risk varies across exposure patterns and medical histories. Dehydration, prolonged exertion, sleep deprivation, infection, and concurrent substances can compound medical risk. Severe headache, new weakness, chest pain, fainting, or dangerously high temperature warrants emergency assessment. The ASAM/AAAP guideline describes acute medical complications and appropriate escalation.

Sleep and appetite disruption can contribute to exhaustion, poor nutrition, weight changes, cognitive difficulties, and mood symptoms. Dental disease may reflect multiple interacting causes, including dry mouth, bruxism, nutrition, inconsistent oral hygiene, and limited access to dental services. Injection can expose people to bacterial infections, hepatitis, HIV, and endocarditis when equipment or preparation conditions are unsafe. Sexual health risks depend on behavior and context, and should be discussed without assumptions about identity or individual practices. Preventive care therefore includes cardiovascular evaluation when indicated, dental care, nutrition, vaccinations, sexual health services, and testing and treatment of infection. See ASAM/AAAP.

Cognition, mood, and daily functioning

People with persistent heavy use may report difficulty with attention, learning, planning, emotional regulation, and memory. Research findings vary with duration of abstinence, differences in premorbid functioning, other substance use, psychiatric illness, and methodological design. Cross-sectional cognitive differences cannot by themselves prove irreversible injury in every individual. Some functions may improve during sustained abstinence, while others require assessment and rehabilitation. Treatment should accommodate cognitive load with clear instructions, repetition, reminders, and supportive follow-up. NIDA summarizes research on neurological effects and recovery.

Depression, anxiety, irritability, trauma symptoms, and suicidal thinking may occur before, during, or after methamphetamine use. Their origin often becomes clearer through a longitudinal history rather than a single encounter. Concurrent psychiatric treatment is indicated when symptoms are severe, persistent, or clinically significant; clinicians should not assume that all mental symptoms will resolve automatically when use stops. Immediate safety evaluation is essential for suicidal intent, escalating violence risk, or inability to care for basic needs. ASAM/AAAP recommend integrated management of co-occurring psychiatric disorders.

Methamphetamine-Associated Psychosis

Symptoms and clinical significance

Methamphetamine-associated psychosis can include persecutory delusions, auditory or visual hallucinations, intense suspiciousness, disorganized behavior, or severe agitation. Sleep deprivation and repeated exposure may amplify vulnerability. A person may feel watched, threatened, or unable to distinguish frightening perceptions from events. These experiences can undermine judgment and place the person or others at risk, especially when accompanied by fear, confusion, impulsive behavior, or access to weapons. A calm, low-stimulation environment, respectful communication, and prompt professional evaluation are essential. The ASAM/AAAP guideline recommends assessment and management of psychosis as a potentially urgent complication.

Psychotic symptoms may begin during intoxication, emerge around withdrawal, recur with repeated methamphetamine exposure, or persist after acute effects resolve. Some individuals recover quickly with abstinence, sleep restoration, and appropriate care; others experience prolonged or recurrent episodes. A symptom's temporal relationship to methamphetamine is important but does not automatically settle its diagnosis. An accurate assessment considers previous psychotic episodes, family psychiatric history, mood episodes, medication effects, other drugs, delirium, and medical causes. Detailed differential diagnosis is treated separately in the existing Substance-Induced Psychosis and Drug-Induced Psychosis vs. Schizophrenia articles.

How substantial is the risk of persistent psychosis?

A landmark systematic review and meta-analysis followed people with substance-induced psychoses and found a pooled transition to a later schizophrenia diagnosis of approximately 25% across substances. The pooled estimate for psychoses associated with amphetamines was approximately 22%, but it came from five studies and showed wide uncertainty. This is a prognosis estimate among individuals who already experienced a substance-induced psychotic disorder; it is not the risk that every person using methamphetamine will develop schizophrenia. Selection, diagnostic conventions, follow-up duration, and substance mixtures limit individual prediction. Murrie and colleagues provide the underlying analysis.

A 2026 systematic review of substance-induced psychosis examined predictors of response and transition using studies with follow-up periods ranging from months to many years. Temporal onset, premorbid functioning, and the presence of persistent negative symptoms showed clinically relevant associations with prognosis. Evidence concerning family history, abstinence, and neuroimaging was more uncertain. The review addressed substance-induced psychosis broadly, so its pooled findings should not be converted into precise methamphetamine-specific predictions. Any persistent psychosis requires repeated diagnostic review, attention to safety, and continuity of psychiatric care.

Emergency assessment and management

Psychosis accompanied by dangerous agitation, delirium, fever, chest pain, seizures, severe confusion, or suicidal intent is an emergency. Medical teams evaluate airway and circulation, vital signs, hydration, temperature, cardiovascular complications, other exposures, and psychiatric risk. In carefully monitored settings, clinicians may use medications to control agitation or treat psychosis when clinically indicated, with attention to adverse effects and interactions. The choice and duration of medication depend on diagnosis, severity, and ongoing follow-up. People should not attempt to manage severe intoxication or psychosis alone. ASAM/AAAP distinguishes emergency stabilization from ongoing treatment of stimulant use disorder.

Intoxication, the Comedown, and Withdrawal

Intoxication occurs while stimulant effects are active and may involve increased energy, reduced need for sleep, elevated pulse, restlessness, agitation, or psychotic symptoms. Overdose refers to toxic exposure causing serious physiologic or behavioral harm; stimulant overdose may present with cardiovascular complications, seizures, hyperthermia, or life-threatening agitation. The period after prolonged wakefulness or repeated dosing can involve a marked crash with fatigue, increased sleep, depressed mood, and appetite changes. Withdrawal may also include craving, anxiety, irritability, vivid dreams, and cognitive slowing. The pattern varies with dose, chronicity, co-use, and underlying health. ASAM/AAAP gives clinical guidance on assessment and monitoring.

Methamphetamine withdrawal is usually managed primarily with supportive medical and psychological care, sleep and nutrition restoration, symptom assessment, and engagement in longer-term treatment. The most urgent dangers often come from severe depression or suicidality, psychosis, co-occurring medical disease, and simultaneous withdrawal from other substances. Alcohol and benzodiazepine withdrawal can cause life-threatening seizures or delirium and requires specific medically supervised planning when dependence is present. Opioid co-use introduces respiratory-depression and overdose risks. A supervised evaluation is especially important when someone uses multiple substances or has significant psychiatric symptoms. Withdrawal management is one phase of care, not a stand-alone treatment for compulsive methamphetamine use.

Evidence-Based Treatment

Contingency management: strongest behavioral evidence

Contingency management is a structured intervention that provides predictable positive reinforcement for verified treatment-related behaviors, often methamphetamine-negative samples or attendance. It applies well-established learning principles to create immediate alternatives to drug reinforcement. The ASAM/AAAP guideline identifies contingency management as the current standard of care for stimulant use disorder, given its comparative evidence base. A systematic review found positive abstinence outcomes in most included methamphetamine studies. Programs need clear goals, reliable measurement, equitable access, adherence to applicable regulations, and trained clinical oversight.

Contingency management often works best as one component of continuing care. It can support engagement while a person develops coping skills, obtains psychiatric and medical treatment, rebuilds stable routines, or secures housing. Its effectiveness during a program does not guarantee enduring outcomes after incentives end; sustained treatment and follow-up remain important. A 2026 cost-effectiveness model provides economic support for implementation under its assumptions, while modeling cannot replace direct evidence of long-term outcomes in every healthcare system. A broad 2025 network meta-analysis found that certainty for many specific comparisons remained low or very low despite encouraging findings. These assessments answer different questions: clinical guidelines integrate many forms of evidence, whereas network analyses grade certainty for precise outcome comparisons.

Cognitive behavioral therapy, community reinforcement, and motivational work

Cognitive behavioral therapy can help people identify high-risk situations, examine thoughts linked to use, develop coping responses to craving, plan for sleep and mood difficulties, and practice alternative behaviors. Community reinforcement approaches seek to increase access to work, relationships, recreation, and daily experiences that support life without compulsive use. Motivational interviewing helps people explore ambivalence in a collaborative manner and establish personally meaningful goals. These interventions have variable effects across programs and populations, but are reasonable components of an individualized plan, particularly alongside contingency management. ASAM/AAAP recommends combining appropriately selected psychosocial approaches.

A therapeutic plan should account for cognitive difficulties, limited transportation, trauma-related mistrust, financial instability, and competing responsibilities. A treatment method may have sound evidence yet fail to reach people who cannot attend frequent appointments or who face punitive testing policies. Flexible service delivery, patient participation in decisions, and continuity after missed visits may determine whether evidence-based care becomes practically effective. Supportive involvement from family or peers may be useful when chosen by the patient and when relationships are safe.

Medications: what research supports in 2026

As of October 2026, no medication has US Food and Drug Administration approval specifically for methamphetamine use disorder. Clinicians may consider selected medications off-label for particular patients using individualized risk-benefit assessment, recognizing the differences between research signals and approved indications. Medication choice must account for pregnancy, seizure risk, cardiovascular disease, psychiatric comorbidity, opioid use, interactions, and adherence. Prescribing and monitoring are clinical responsibilities; the evidence does not justify self-treatment. ASAM/AAAP describes conditional off-label medication options.

A multisite randomized trial evaluated combined extended-release naltrexone and bupropion in adults with moderate or severe methamphetamine use disorder. The weighted response was 13.6% with active treatment and 2.5% with placebo over the trial's sequential stages. This statistically significant absolute difference of 11.1 percentage points indicates a possible treatment option for selected patients while illustrating that most participants did not meet the trial's strict response definition. Results should be interpreted with attention to study duration, eligibility criteria, adverse events, and the fact that this regimen is not an FDA-approved methamphetamine use disorder treatment. Trivedi and colleagues, 2021.

Research on mirtazapine initially included smaller randomized studies in specific sexual-minority populations. A broader multisite phase 3 randomized trial published in April 2026 examined mirtazapine in routine clinical care and found a modest additional reduction in methamphetamine use: an estimated 2.2 fewer days of use over a 28-day period at twelve weeks compared with placebo. Statistical significance was reported, and no unexpected safety signal was identified, but sleepiness, tolerability, short follow-up, and the modest magnitude of benefit are relevant in decisions about use. The findings expand the evidence while leaving longer-term comparative effectiveness uncertain. McKetin and colleagues, 2026; earlier context in Coffin and colleagues, 2020.

Other agents, including various antidepressants and prescription psychostimulants, have been investigated in heterogeneous trials. Some outcomes appear promising in particular populations, but results do not establish a general medication standard comparable to established pharmacotherapies for opioid use disorder. A network meta-analysis of 72 trials and 6,836 adults concluded that no evaluated intervention had moderate- to high-certainty evidence for important changes across all patient-important outcomes. This finding should motivate careful clinical interpretation rather than a claim that all treatment is ineffective. Behavioral interventions, integrated clinical care, and harm reduction retain important roles.

Treating co-occurring disorders

The presence of psychosis, depression, posttraumatic symptoms, ADHD, anxiety, or another substance use disorder should lead to coordinated assessment and, when indicated, concurrent treatment. Psychiatric medication may be appropriate for an independently diagnosed condition even when it does not directly treat methamphetamine use disorder. Patients with co-occurring opioid use disorder should receive evidence-based opioid treatment rather than being required to resolve stimulant use first. For persistent psychosis, appropriate psychiatric treatment and follow-up are essential. Care coordination helps avoid medication interactions, fragmented referrals, and contradictory treatment plans. ASAM/AAAP explicitly endorses concurrent treatment of clinically relevant comorbidity.

Harm Reduction and Emergency Safety

Harm reduction addresses preventable injury and infection while supporting engagement in healthcare. It may include avoiding use alone, access to drug checking where reliable services exist, sterile injection equipment, safer-sex resources, HIV and hepatitis testing, vaccination, oral health support, and education about contamination or unexpected exposure. Because the illicit stimulant supply can contain opioids, people who may encounter opioids should have access to naloxone and training to recognize opioid overdose. Naloxone reverses opioid toxicity; it does not reverse the primary cardiovascular or hyperthermic effects of methamphetamine. Emergency services should be called for unresponsiveness or breathing abnormalities, even if naloxone is given. ASAM/AAAP includes secondary and tertiary prevention guidance.

Safety conversations should address the real circumstances of use, including isolation, sexual coercion or violence, unsafe housing, and the availability of emergency services. Clinicians can ask about overdose history, unexpected sedation, concurrent opioid or sedative use, injection-related infections, and barriers to care without making moral judgments. An individual may seek care before being ready for abstinence, and treatment can still improve survival and functioning. Reducing infection and overdose risk is a meaningful health outcome that can coexist with longer-term goals for methamphetamine reduction or abstinence.

Pregnancy, Adolescence, and Other Clinical Contexts

Pregnancy requires timely, individualized obstetric and addiction assessment. Methamphetamine exposure may occur alongside poor nutrition, hypertensive disease, smoking, unstable housing, trauma, and delayed prenatal care. Observational associations with adverse pregnancy outcomes need careful control for such confounders; they do not support attributing every complication to a single exposure. Integrated prenatal care, nonpunitive engagement, assessment of psychiatric and other substance use disorders, and attention to infant needs are important. Decisions about medications require specialized obstetric evaluation because a trial in nonpregnant adults does not establish prenatal safety. ASAM/AAAP provides population-specific recommendations.

Adolescents and young adults need developmentally appropriate assessment that addresses school, family safety, peer context, sexual health, psychiatric symptoms, and confidentiality. Evidence from adult medication studies should not be automatically generalized to young people. Supportive family involvement may help when appropriate and safe. For people experiencing homelessness or incarceration, practical access to follow-up, uninterrupted psychiatric care, housing, and infection prevention can influence outcomes as much as a specific counseling modality. Older adults and patients with cardiovascular disease may require closer medical monitoring because physiologic reserve and comorbid conditions change risk. The ASAM/AAAP guideline recommends responsive care across ages and settings.

Recovery, Recurrence, and Long-Term Functioning

Recovery is a process of improving health, self-direction, safety, and functioning over time. Diagnostic remission describes the status of clinical criteria during a defined period; recovery additionally involves quality of life, relationships, stability, and the patient's own goals. Recurrence of use after improvement is a clinical event that calls for reassessment of cues, needs, and treatment, rather than dismissal from care. The term relapse is widely used but may obscure the range between a single episode of reuse and a return to a sustained harmful pattern. Researchers should state their outcome definitions clearly, including abstinence, reduced frequency, clinical severity, functioning, treatment retention, and subjective wellbeing. SAMHSA's recovery framework emphasizes health, home, purpose, and community.

Early recovery may require stabilizing sleep, appetite, depression, and social routines. Later phases often center on work or study, housing, reconnection with safe relationships, management of other illnesses, and coping with unexpected stress. Some people benefit from mutual-help organizations or peer recovery support, while others prefer clinical therapy, family support, or different community resources. Recovery trajectories vary and should be assessed longitudinally. Even when complete cessation is a desired outcome, incremental improvements in safety and functioning deserve clinical attention. Repeated engagement after recurrence can preserve access to treatment and prevent harms.

How Clinicians and Patients Can Make a Care Plan

A collaborative plan begins with immediate safety assessment. Medical instability, psychosis, suicidal intent, severe withdrawal from another substance, or impaired capacity may require emergency or hospital care. Once stabilized, the clinician and patient review the pattern of methamphetamine use, diagnostic severity, other substances, psychiatric conditions, medical risk, prior treatments, and practical obstacles. A treatment setting is then matched to the person's needs, with the level of care adjusted as symptoms change. The ASAM/AAAP guideline provides detailed recommendations for these decisions.

For ongoing treatment, clinicians can offer contingency management when accessible and combine it with psychological therapy, integrated medical and psychiatric services, harm reduction, and recovery supports. Treatment goals should be explicit and measurable but responsive to clinical changes. Progress may include fewer days of use, improved sleep, reduced emergency visits, restored employment or education, safer relationships, and better mood. Testing, where clinically useful and consented to, is one source of information rather than the whole definition of success. Treatment should continue across transitions from emergency department to community clinic or from residential to outpatient care.

Evidence Quality and Scientific Debates

The evidence is strongest for contingency management as a behavioral treatment during active program participation, the need for acute medical stabilization in serious stimulant toxicity, and concurrent care for psychiatric and medical comorbidity. The medication literature is developing, with some randomized evidence for naltrexone–bupropion and mirtazapine but smaller effects, population restrictions, and limits on long-term follow-up. The ASAM/AAAP guideline offers practice recommendations that combine study data with expert judgment; the 2025 network meta-analysis highlights why graded certainty can remain low for some precise comparative outcomes.

Estimates of psychosis persistence and transition to schizophrenia come largely from observational cohorts and are vulnerable to diagnostic misclassification, selective follow-up, and co-exposure. Neuroimaging and cognitive associations may reflect several pathways and do not provide an individually predictive brain test. Research samples may underrepresent pregnant patients, adolescents, people with severe psychiatric illness, rural populations, and those facing unstable housing. Future inference depends on transparent outcomes, representative recruitment, longer follow-up, and direct comparisons of accessible treatment packages. A 2026 review of prognostic factors illustrates why monitoring over time remains necessary.

Frequently Asked Questions

Can someone use methamphetamine without having a disorder?

Yes. Exposure, risky use, and diagnosed methamphetamine use disorder are different clinical categories. A diagnosis requires an established pattern of symptoms and clinically meaningful impact assessed by a qualified clinician. Someone without a disorder can still experience an emergency, infection, or other harm from a single exposure. ASAM/AAAP recommends screening and prevention across levels of risk.

Does methamphetamine use always cause psychosis?

No. Psychosis risk increases in some patterns of use and with interacting vulnerabilities, but individual outcomes differ. People who experience paranoia, hallucinations, or delusions need assessment, especially if they are frightened, confused, or unsafe. Persistent or recurrent symptoms require psychiatric follow-up even after methamphetamine use has stopped. See Murrie and colleagues.

Does psychosis mean the person has schizophrenia?

Psychosis is a syndrome with several potential causes. Methamphetamine exposure can produce psychotic symptoms, coexist with a primary psychotic disorder, or precede an enduring diagnosis. Timing, previous history, sustained observation, and evaluation of medical and psychiatric alternatives inform diagnosis. See the related Drug-Induced Psychosis vs. Schizophrenia evidence guide.

Is there an approved medicine that cures methamphetamine use disorder?

There is no FDA-approved medicine specifically for methamphetamine use disorder as of October 2026. Selected off-label medicines have randomized trial evidence for modest benefit in certain patients, and prescribing requires clinical supervision. Contingency management remains the best-supported specific behavioral intervention. See ASAM/AAAP, Trivedi et al., and McKetin et al..

What happens after methamphetamine withdrawal?

Sleep disruption, low mood, fatigue, and craving may persist beyond the acute period. Care focuses on monitoring mood and safety, restoring routines, treating co-occurring conditions, and continuing evidence-based behavioral treatment. Suicidal thinking, severe depression, confusion, or psychosis calls for prompt clinical assessment. ASAM/AAAP discusses post-acute symptoms and continuing care.

Can recovery include reduced use and better functioning?

Patient-centered recovery can be tracked through improvements in safety, quality of life, functioning, and substance-use patterns. Diagnostic remission and broader recovery are related but distinct concepts. The clinical plan should specify meaningful goals and reassess them over time, rather than assume that every person's trajectory is identical. SAMHSA describes recovery as a multidimensional process.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — the central scientific framework for diagnosis, treatment, harm reduction, and recovery.

Substance-Induced Psychosis: Causes, Symptoms, and Treatment — psychiatric assessment of psychosis linked to substances and medications.

Drug-Induced Psychosis vs. Schizophrenia: How Clinicians Tell the Difference — temporal assessment and differential diagnosis of persistent psychosis.

Schizophrenia and Substance Use Disorders: Dual-Diagnosis Care — coordinated treatment when substance use and a psychotic disorder coexist.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — evaluation of co-occurring anxiety and substance-related symptoms.

Stimulant Use Disorder: Methamphetamine, Cocaine, and Treatment — shared diagnostic and treatment principles for cocaine and amphetamine-type stimulant disorders.

Cocaine Use Disorder: Symptoms, Cardiovascular Risks, and Treatment — cocaine-specific disorder, acute cardiovascular risks, and evidence-based care.

Contingency Management for Substance Use Disorders: Research and Effectiveness — incentive-based behavioral treatment and outcomes for stimulant and other disorders.

References

American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. Journal of Addiction Medicine, 18(1S), 1–56. https://doi.org/10.1097/ADM.0000000000001299.

Brown, H. D., and DeFulio, A. (2020). Contingency management for the treatment of methamphetamine use disorder: A systematic review. Drug and Alcohol Dependence, 216, 108307. https://doi.org/10.1016/j.drugalcdep.2020.108307.

Coffin, P. O., Santos, G., Hern, J., et al. (2020). Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: A placebo-controlled randomized clinical trial. JAMA Psychiatry, 77(3), 246–255. https://doi.org/10.1001/jamapsychiatry.2019.3655.

Khalili, M., Sadeghirad, B., Bach, P., et al. (2025). Management of amphetamine and methamphetamine use disorders: A systematic review and network meta-analysis of randomized trials. International Journal of Mental Health and Addiction, 23, 4768–4786. https://doi.org/10.1007/s11469-024-01379-w.

McKetin, R., Shoptaw, S., Saunders, L., et al. (2026). Mirtazapine for methamphetamine use disorder: A randomized clinical trial. JAMA Psychiatry, 83(6), 581–589. https://doi.org/10.1001/jamapsychiatry.2026.0159.

Murrie, B., Lappin, J., Large, M., and Sara, G. (2020). Transition of substance-induced, brief, and atypical psychoses to schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin, 46(3), 505–516. https://doi.org/10.1093/schbul/sbz102.

National Institute on Drug Abuse. (n.d.). Methamphetamine. https://nida.nih.gov/research-topics/methamphetamine.

Qian, G. L., Chen, Y., Rawson, R. A., Humphreys, K., and Brandeau, M. L. (2026). Cost-effectiveness of contingency management for methamphetamine use disorder: A model-based analysis. Addiction, 121(8), 2127–2140. https://doi.org/10.1111/add.70377.

Ricci, V., Chiappini, S., Martinotti, G., and Maina, G. (2026). From substance-induced psychosis to schizophrenia: Predictors of treatment response and transition to chronic psychotic illness—A systematic review. Schizophrenia Research, 295, 292–316. https://doi.org/10.1016/j.schres.2026.02.022.

Substance Abuse and Mental Health Services Administration. (n.d.). About recovery. https://www.samhsa.gov/substance-use/recovery/about.

Trivedi, M. H., Walker, R., Ling, W., et al. (2021). Bupropion and naltrexone in methamphetamine use disorder. New England Journal of Medicine, 384, 140–153. https://doi.org/10.1056/NEJMoa2020214.